Skip to content
Companies

Pheast Therapeutics

Antibody that blocks CD24 so macrophages attack cancer

Raised to date

$99.8M

of $115.2M offered across 2 Form D filings

Still open
$15.4M
Investors
7
Last filed
Oct 16, 2025

About

Pheast Therapeutics, Inc. is a preclinical-stage biotechnology company focused on developing novel immuno-oncology therapies. The company is pioneering a new approach to cancer treatment by targeting innate immune evasion pathways, specifically harnessing the power of macrophages to recognize and eliminate cancer cells. Pheast's innovative approach aims to address the limitations of current immunotherapies and offer solutions for aggressive cancers.

Targeting innate immune checkpoints

Funding

$75.3M round, first sold Jan 2022$75.3M sold20222024
Now
  • EquityFiled Oct 16, 2025Form D
    $24.6M/ $40M
  • EquityFiled Apr 10, 2025Form D/A
    $75.3M/ $75.3M

Product

PHST001

Monoclonal antibody

PHST001 is an innovative monoclonal antibody targeting CD24, a "don't eat me" signal expressed by various cancer cells, including those found in ovarian and triple-negative breast cancer. By specifically binding to and blocking CD24, PHST001 promotes macrophage-mediated phagocytosis, facilitating the immune system's ability to recognize, engulf, and destroy cancer cells. Preclinical studies have demonstrated the potential of PHST001 to significantly reduce and even eradicate tumors in animal models, highlighting its promise as a novel cancer therapy.

  • Monoclonal antibody
  • Targets CD24
  • Promotes macrophage-mediated phagocytosis

Built for

Patients with difficult-to-treat and aggressive cancers

People on file